Viranova

Viranova is an Irvine, California-based biotechnology company pioneering AI-native drug development to combat herpes simplex virus type 1 (HSV-1), a leading cause of corneal blindness. We are focused on developing antisense oligonucleotide therapeutics that silence ICP0, a critical viral protein, effectively preventing HSV-1 reactivation and protecting vision. Our approach offers a novel strategy for treating HSV-1-associated ocular disease, including herpes simplex keratitis. Viranova’s innovative technology represents a significant advancement in antiviral therapeutics, targeting the root cause of the infection rather than managing symptoms.

We specialize in the design and development of gapmer therapeutics, utilizing artificial intelligence to create highly effective and targeted treatments. Our research is specifically geared towards addressing the global burden of HSV-1, particularly its impact on vision.

Viranova is committed to translating cutting-edge scientific discoveries into tangible solutions for patients suffering from debilitating viral infections. We are dedicated to advancing the field of antiviral therapeutics and improving patient outcomes through innovative, AI-driven drug development.